Table 3.

Summary of studies reporting outcomes of patients with T2 laryngeal cancer

Author, Year	Follow-up Time	Total No. of Pts.	All stages Included	No. of patients with T2 larynx cancer	Treatment modality	LC rates, %	LC rates with laryngeal preservation, %	uLC rates, %	OS rates, %	Cause-specific survival rates, %
Fletcher et al., 1980 27	NR	507	T2	175	RT	74
Harwood et al., 1981 28	NR	244	T2	244	RT	69 (5-y)
Wang, 1997 29	NR	902	T1-T2	T2a 145 T2b 92	RT	77 (5-y) 71 (5-y)				92 (5-y) 84 (5-y)
Le et al., 1997 30	Median 9.7 y	398	T1-T2	83	RT	70 (5-y)		uLRC 91 (5-y)	63 (10-y)	91 (10-y)
Warde et al 1998 31	Median 6.8 y	735	T1-T2	286	RT	69 (5-y)
Garden et al., 2003 32	Median 6.8 y	230	T2	230	RT	72 (5-y)			73 (5-y)	92 (5-y)
Short et al., 2006 33	Median 4.9 y	145	T1-T2	43	RT	80 (5-y LRC)
Taguchi et al., 2006 34	Median 32 mo	20	T2	20	CCRT	95 (3-y)	100 (3-y)		100 (3-y)
Hafidh et al., 2009 35	Mean 37 mo	373	T1-T4	38	RT	63.3 (5-y)
Chera et al., 2010 7	Median 12 y	585	T1-T2	T2a 165** T2b 95	RT	T2a: 80 (5-y) T2b: 70 (5-y)		T2a 81 (5-y) T2b 74 (5-y)	T2a 76 (5-y) T2b 78 (5-y)	T2a 94 (5-y) T2b 90 (5-y)
Kim et al., 2012 12	Median 7.1 y	157	T1-T2	32	RT	62 (5-y)
Furusaka et al., 2012 36	Median 9.4 y	57	T2	57	RT		60.4 (5-yr) 50.1 (10-yr)		88.5 (5-y) 73.5 (10-y)
Ermis et al., 2015 37	Median 72 mo	132	T1-T2	64	RT	80.9 (5-y)		95.8 (5-y)

Abbreviations: NR, not reported; y, year(s); mo, month(s); RT, radiation therapy; CCRT, concurrent chemoradiation; LC, local control; LRC: loco-regional control; uLC, ultimate local control; uLRC, ultimate loco-regional control

^**T2a and T2b classifications were based on the 2^nd edition of the American Joint Committee on Cancer (AJCC) staging system. T2 is not subdivided into T2a and T2b in the 8^th edition of the AJCC staging system.